191 related articles for article (PubMed ID: 27764093)
21. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
22. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract][Full Text] [Related]
23. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
24. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM; Mostafa MF; El-Gendi AM
Pathol Oncol Res; 2012 Apr; 18(2):459-69. PubMed ID: 22057638
[TBL] [Abstract][Full Text] [Related]
25. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.
Moon H; Lee CS; Inder KL; Sharma S; Choi E; Black DM; Lê Cao KA; Winterford C; Coward JI; Ling MT; ; Craik DJ; Parton RG; Russell PJ; Hill MM
Oncogene; 2014 Jul; 33(27):3561-70. PubMed ID: 23934189
[TBL] [Abstract][Full Text] [Related]
26. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
27. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.
Kasperzyk JL; Shappley WV; Kenfield SA; Mucci LA; Kurth T; Ma J; Stampfer MJ; Sanda MG
J Urol; 2011 Nov; 186(5):1862-7. PubMed ID: 21944095
[TBL] [Abstract][Full Text] [Related]
28. Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Cancer Genomics Proteomics; 2015; 12(6):391-6. PubMed ID: 26543085
[TBL] [Abstract][Full Text] [Related]
29. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.
Langeberg WJ; Tahir SA; Feng Z; Kwon EM; Ostrander EA; Thompson TC; Stanford JL
Prostate; 2010 Jun; 70(9):1020-35. PubMed ID: 20209490
[TBL] [Abstract][Full Text] [Related]
30. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
31. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.
Yang G; Truong LD; Wheeler TM; Thompson TC
Cancer Res; 1999 Nov; 59(22):5719-23. PubMed ID: 10582690
[TBL] [Abstract][Full Text] [Related]
32. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Ruela-de-Sousa RR; Hoekstra E; Hoogland AM; Souza Queiroz KC; Peppelenbosch MP; Stubbs AP; Pelizzaro-Rocha K; van Leenders GJLH; Jenster G; Aoyama H; Ferreira CV; Fuhler GM
Eur Urol; 2016 Apr; 69(4):710-719. PubMed ID: 26159288
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
34. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
35. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
36. High progesterone receptor expression in prostate cancer is associated with clinical failure.
Grindstad T; Andersen S; Al-Saad S; Donnem T; Kiselev Y; Nordahl Melbø-Jørgensen C; Skjefstad K; Busund LT; Bremnes RM; Richardsen E
PLoS One; 2015; 10(2):e0116691. PubMed ID: 25723513
[TBL] [Abstract][Full Text] [Related]
37. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression.
Steiner I; Jung K; Miller K; Stephan C; Erbersdobler A
Oncol Rep; 2012 Feb; 27(2):389-95. PubMed ID: 22075971
[TBL] [Abstract][Full Text] [Related]
38. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival.
Zhao Z; Han FH; Yang SB; Hua LX; Wu JH; Zhan WH
World J Gastroenterol; 2015 Jan; 21(4):1140-7. PubMed ID: 25632186
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy versus watchful waiting in early prostate cancer.
Bill-Axelson A; Holmberg L; Ruutu M; Garmo H; Stark JR; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Steineck G; Adami HO; Johansson JE;
N Engl J Med; 2011 May; 364(18):1708-17. PubMed ID: 21542742
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
Adamo H; Hammarsten P; Hägglöf C; Dahl Scherdin T; Egevad L; Stattin P; Halin Bergström S; Bergh A
Prostate; 2019 Apr; 79(5):435-445. PubMed ID: 30536410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
